文献速递主动脉疾病

胸主动脉腔内修复联合左锁骨下动脉血运重建治疗B型主动脉夹层:开窗术者改良支架与一体式单分支支架的疗效比较

Thoracic Endovascular Aortic Repair with Left Subclavian Artery Revascularization for Type B Aortic Dissection: Outcomes of Fenestrated Physician-Modified Stent-Graft Versus Unibody Single-Branched Stent-Graft.
PubMed 文献 · Ann Vasc Surg · 2025-04-18

回顾性分析2019年1月至2022年7月接受开窗术者改良支架(f-PMSG,n=37)或Castor一体式单分支支架(n=43)行胸主动脉腔内修复联合左锁骨下动脉血运重建的B型主动脉夹层患者。两组技术成功率均为100%,f-PMSG组无早期死亡,Castor组院内1例(2.3%)死于多器官衰竭。f-PMSG组随访中4例(10.8%)死亡(含1例主动脉相关死亡),Castor组4例(9.3%)死因不明;术后1年分支动脉通畅率分别为92.0%和88.4%。

要点

  • 两组技术成功率均为100%,f-PMSG组无早期死亡,Castor组院内死亡1例(2.3%)。
  • f-PMSG组随访死亡4例(10.8%,含1例主动脉相关),Castor组死亡4例(9.3%,死因不明)。
  • 术后1年分支动脉通畅率f-PMSG组92.0%,Castor组88.4%。

核心结论

  • 对于近端锚定区不足的TBAD患者,使用Castor单分支支架或f-PMSG行TEVAR联合LSA血运重建是最佳治疗选择。
  • 与f-PMSG相比,Castor单分支支架是一种即用型产品,适用于TBAD及血运重建。

研究设计与样本

  • 回顾性分析2019年1月至2022年7月接受f-PMSG(n=37)或Castor一体式单分支支架(n=43)治疗的TBAD患者。
  • 主要终点为30天及随访期间的全因死亡、主动脉相关死亡和重大并发症;次要终点为内漏、再干预和分支动脉通畅率。

主要发现

  • 两组技术成功率均为100%。
  • f-PMSG组无早期死亡;Castor组住院期间1例(2.3%)死于多器官衰竭。
  • f-PMSG组中位随访53.6个月(范围34-60个月),Castor组41个月(范围24-42个月)。
  • f-PMSG组死亡4例(10.8%),其中主动脉相关死亡1例;Castor组死亡4例(9.3%),死因不明。
  • 术后1年分支动脉通畅率f-PMSG组为92.0%,Castor组为88.4%。

临床怎么用

  • 作者认为,对于近端锚定区不足的TBAD患者,TEVAR联合Castor单分支支架或f-PMSG行LSA血运重建是最佳治疗选择。
  • 作者指出,Castor单分支支架为即用型产品,适用于TBAD及血运重建。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To evaluate the outcomes of thoracic endovascular aortic repair (TEVAR) with fenestrated physician-modified stent-grafts (f-PMSG) or Castor unibody single-branched stent-graft to revascularize left subclavian artery (LSA) in type B aortic dissection (TBAD) patients. METHODS: A retrospective analysis was conducted of TBAD patients treated f-PMSG (n = 37) or Castor unibody single-branched stent-graft (n = 43) from January 2019 to July 2022. The primary endpoints at 30 days and during follow-up were overall mortality, aortic-related mortality, and major complications. The secondary endpoints were endoleak, reintervention, and branch artery patency. RESULTS: Technical success was 100% in both groups. No patient had early mortality in f-PMSG group, and 1 (2.3%) patient died of multiorgan failure during hospitalization in Castor group. The median follow-up was 53.6 months (range, 34-60 mouths) and 41 months (range, 24-42 months) in f-PMSG and Castor group, respectively. In f-PMSG group, 4 (10.8%) patients died, including 1 aortic-related mortality. In Castor group, 4 (9.3%) patients died of unknown reason. At 1 year after the operation, the branch artery patency rate was 92.0% and 88.4% in f-PMSG and Castor group, respectively. CONCLUSION: For patients with TBAD, TEVAR with Castor single-branched stent-graft or f-PMSG is optimal treatment option when proximal landing zone is insufficient. Compared with f-PMSG, Castor single-branched stent-graft was an off-the-shelf product indicated for TBAD and revascularization.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Li X, Xu B, Zhao W, et al. Thoracic Endovascular Aortic Repair with Left Subclavian Artery Revascularization for Type B Aortic Dissection: Outcomes of Fenestrated Physician-Modified Stent-Graft Versus Unibody Single-Branched Stent-Graft. Ann Vasc Surg. 2025. PMID: 40254155. doi:10.1016/j.avsg.2025.04.113

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。